What main concern is associated with the treatment of porphyria cutanea tarda?

The main concern associated with the treatment of porphyria cutanea tarda, or PCT, is indeed iron overload. This condition is characterized by a deficiency in the enzyme uroporphyrinogen decarboxylase, which leads to the accumulation of porphyrins in the liver and skin. The treatment often involves phlebotomy or the use of hydroxychloroquine, both of which can lead to increased iron absorption and potential iron overload in the body.

Iron overload can result in damage to various organs, most notably the liver, heart, and pancreas, leading to complications like cirrhosis, diabetes, and heart disease. This is especially relevant in PCT since patients may already have hepatic dysfunction due to the underlying disorder.

Monitoring and managing iron levels is thus crucial during the treatment of PCT to prevent associated complications related to excessive iron accumulation. Proper management helps ensure that the treatment does not exacerbate the patient's condition or lead to new health issues. Understanding the relationship between treatment and iron metabolism is vital for anyone dealing with porphyria cutanea tarda.